SGRY VS ALKS Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatility
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatility

Performance

SGRY
10/100

SGRY returned 4.97% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

ALKS
10/100

ALKS returned 4.91% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

SGRY
61/100

9 analysts offer 12-month price targets for SGRY. Together, they have an average target of 64, the most optimistic target put SGRY at 64 within 12-months and the most pessimistic has SGRY at 64.

ALKS
63/100

12 analysts offer 12-month price targets for ALKS. Together, they have an average target of 30.33, the most optimistic target put ALKS at 35 within 12-months and the most pessimistic has ALKS at 27.

Technicals

SGRY
64/100

SGRY receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

ALKS
10/100

ALKS receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

SGRY
10/100

SGRY has missed earnings 11 times in the last 20 quarters.

ALKS
100/100

ALKS has missed earnings 0 times in the last 20 quarters.

Profit

SGRY
61/100

Out of the last 20 quarters, SGRY has had 14 profitable quarters and has increased their profits year over year on 7 of them.

ALKS
25/100

Out of the last 20 quarters, ALKS has had 4 profitable quarters and has increased their profits year over year on 4 of them.

Volatility

SGRY
47/100

SGRY has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

ALKS
46/100

ALKS has had a lower than average amount of volatility over the last 12 months giving it a score of 46 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Surgery Partners, Inc. Common Stock Summary

Nasdaq / SGRY
Healthcare
Medical - Care Facilities
Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2021, it owned or operated a portfolio of 126 surgical facilities, including 108 ambulatory surgical centers and 18 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.

Alkermes Inc. plc Summary

Nasdaq / ALKS
Healthcare
Biotechnology
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.